News

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.

These data from the DISCOVER-2 study highlight improvements in patient-reported outcomes for patients who are biologic-naïve and have PsA.

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.

Participants with an RA risk had various opinions on preventive measures, from being on board, needing to be swayed by a doctor, and fearing the intervention.

The analysis of NHANES 2005-2016 data found exposure to thiocyanate, either alone or in combination with perchlorate and nitrate, was associated with arthritis vulnerability and inflammation.

Despite being a rare occurrence, the infection was linked to deaths in 1 in 5 observed patients.

A new study found RA patients with concomitant Sjögren’s disease were more likely to fail TNFi treatment than the treatments of other mode of action biologics and JAKi.

Results showed co-administration of methotrexate with pegloticase led to similar rates of urate-lowering response and adverse events in patients with and without CKD.

This analysis indicates that a combined, 22-week Mediterranean and ketogenic diet for patients with psoriatic disease led to beneficial results.

A 6-week bodyweight exercise program led to improved muscle strength, range of motion, and physical fitness test results in female patients with RA.

A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.

A comparison of the urate-lowering therapies shows discrepancies in short- and long-term use outcomes.

A new study evaluated gender differences in physical functioning, sexual dysfunction, depression, fatigue, pain, and loneliness among RA patients using and not using methotrexate.

Findings suggest a positive association between valine, leucine, and isoleucine intake with RA risk, although total and individual dietary BCAA intake were not related to disease activity parameters.

These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.

Of 1156 participants with chronic musculoskeletal pain, 1073 participants retired at an earlier age. Participants with chronic pain were 1.25 times more likely to stop working.

New 5 year data from the phase 3 SELECT-COMPARE trial suggest a patient with RA not responding to adalimumab or upadacitinib may fare better switching to the other.

The findings in this research letter allow for greater understanding of residual joint pain modulators, with the overall goal being to improve health outcomes for those with PsA.

An analysis of data from more than 5 million people suggests rheumatic and immune-mediated diseases were associated with increased rates of childlessness and elevated risk of adverse pregnancy outcomes.

These data on patients with psoriatic arthritis point to risk levels for new adalimumab users as well as users of ustekinumab and etanercept.

Aquatic therapy for women with fibromyalgia in Spain is better than land-based therapy for reducing pain levels and improving sleep quality, as seen at the 6-week follow-up.

From 1990 to 2019, the prevalence, incidence, and disability-adjusted life years of gout worldwide increased by 22.4%, 18%, and 22.2%, respectively.

A new study found the achievement of remission or low disease activity for PsA patients on apremilast was 53.8% by month 12.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

Participants with RA had a 1.66-fold greater risk of depression compared to participants without RA, a new study found.

Test your knowledge of the ACR's guideline for the management of gout with this quiz!

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

After propensity score matching, patients with COVID-19 were at an increased risk for AIRD when compared with both uninfected controls and influenza-infected patients.